All Stories

  1. What Can We Save for the First-Line Treatment of NSCLC in 2016?

    Article • World Journal of Oncology, January 2017, Elmer Press, Inc.

    Dr David Rossi

  2. Secondary Bone Marrow Malignancies after Adjuvant Chemotherapy for Breast Cancer: A Report of 2 Cases and a Review of the Literature

    Article • Tumori Journal, November 2016, SAGE Publications

    Dr David Rossi

  3. Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC

    Article • January 2012, Elmer Press, Inc.

    Dr David Rossi

  4. HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer

    Article • March 2011, Wiley

    Dr David Rossi

  5. “Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07)

    Article • January 2011, Elmer Press, Inc.

    Dr David Rossi

  6. Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

    Article • Targeted Oncology, October 2010, Springer Science + Business Media

    Dr David Rossi

  7. High safety profile and activity of oral vinorelbine in an elderly patient with metastatic breast cancer

    Article • Breast Cancer, September 2009, Springer Science + Business Media

    Dr David Rossi

  8. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy

    Article • British Journal of Cancer, March 2009, Springer Science + Business Media

    Dr David Rossi

  9. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

    Article • British Journal of Cancer, October 2008, Springer Science + Business Media

    Dr David Rossi

  10. Weekly Paclitaxel in Elderly Patients (Aged ≥ 70 Years) with Advanced Non–Small-Cell Lung Cancer: An Alternative Choice? Results of a Phase II Study

    Article • September 2008, Elsevier

    Dr David Rossi

  11. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer

    Article • Anti-Cancer Drugs, August 2008, Wolters Kluwer Health

    Dr David Rossi

  12. Safety Profile and Activity of Lower Capecitabine Dose in Patients with Metastatic Breast Cancer

    Article • Clinical Breast Cancer, December 2007, Elsevier

    Dr David Rossi

  13. A Phase II Study of Single-Agent Oral Vinorelbine in Patients with Pretreated Advanced Non–Small-Cell Lung Cancer

    Article • Clinical Lung Cancer, May 2007, Elsevier

    Dr David Rossi

  14. Pyridoxine as Prophylactic Therapy for Palmar-Plantar Erythrodysesthesia Associated with Administration of Pegylated Liposomal Doxorubicin (Caelyx): A Single-Center Experience

    Article • Oncology, January 2007, Karger Publishers

    Dr David Rossi

  15. Durable Response To Capecitabine (Xeloda; Roche) In An Elderly Patient With Liver And Bone Metastases Of Breast Cancer

    Article • The Internet Journal of Oncology, January 2006, Internet Scientific Publishers, LLC

    Dr David Rossi

  16. The Management Of Double Neoplasms: A Case Of A Patient With Small Cell Lung And Gastric Cancer Successfully Treated With Chemotherapy

    Article • The Internet Journal of Oncology, January 2005, Internet Scientific Publishers, LLC

    Dr David Rossi

  17. Thrombocytosis and Gemcitabine

    Article • The Internet Journal of Oncology, January 2002, Internet Scientific Publishers, LLC

    Dr David Rossi

  18. Different doses of pamidronate in patients with painful osteolytic bone metastases

    Article • Supportive Care in Cancer, February 1998, Springer Science + Business Media

    Dr David Rossi

  19. Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer

    Article • Cancer Chemotherapy and Pharmacology, July 1996, Springer Science + Business Media

    Dr David Rossi